Our expert says:
“Like your yourself, the pharmaceutical industry is grappling with the implications of the proposed changes to the costs associated with the manufacturing and distribution of medicines. The Department of Healthcare would on a regular basis investigate the manner in which the complete healthcare system works from manufacturers, suppliers, providers and those who require the care. One of these investigations has been into the relative cost of medicines. It is generally accepted that around 30% of the overall cost of medical schemes is associated with the provision of medicine. Medical schemes often therefore correctly justify increases in contributions on the basis of the costs in the different areas, like medicines. The Department is trying to deal with this issue decisively.
Until recently most medicines had in-force patents and the industry was to a large extent dependent the original developers and suppliers of these medicines, and the prices that they set. As these patents expired it has allowed other players to come into the market, resulting in generic medicines – almost identical in that they have a similar chemical make up, but at a substantially reduced price (no need for recovery of R&D). The biggest question of all is whether it is reasonable for companies to significantly profiteer from an enterprise that is so fundamentally social, in both its benefits (healing the sick) and the strains on the state, or product providers, (costs of these services). Perhaps if the state paid for R&D then all would be well – but then they would simply be transferring the cost from the private sector to the state sector.
The pharmaceutical industry have 3 months to respond to the proposals by the minister, and I am sure that while there will be some significant savings there will also be some significant compromises. This industry is big business and our tendency towards capitalistic values will not allow what is essentially a socialistic regime to succeed. Either they can make money or they invest their money elsewhere. Making some money is obviously better than making no money. The industry has employed financial specialists to model the value chain with the intention of producing a report that recommends not only how much can be trimmed but also the rate at which it can be trimmed.
The first of the actions to be implemented, from May, will be the banning of the discounting and promotion schemes on certain products whose prices in the past were recovered from the prices of other products.
Regrettably we are not going to see the benefits of the proposed statement for some time to come, and my guess is that it will be gradual.”
The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal
advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.